Description
Almonertinib is an investigational drug being studied as a potential treatment for advanced solid tumors, including colorectal cancer, specifically in patients whose tumors have a KRAS mutation. KRAS mutations are common in colorectal cancer and can make the cancer resistant to certain standard treatments. This drug is currently in early-phase clinical trials (Phase 1) to determine its safety and how well it is tolerated when given in combination with another drug, palbociclib. Researchers are also looking for early signs that the drug combination might be effective in shrinking tumors or slowing their growth in patients with KRAS-mutated cancers. It is important to remember that almonertinib is not yet approved for use and is only available in the context of clinical trials.
Mechanism of Action
Almonertinib is a targeted therapy. It is designed to target a specific protein involved in the growth and spread of cancer cells. The specific protein targeted by almonertinib is being investigated in clinical trials. By targeting this protein, almonertinib aims to disrupt the signals that tell cancer cells to grow and divide, potentially slowing or stopping tumor growth. It is being studied in combination with palbociclib, which targets different proteins involved in cell division.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.